Deutsche Bank has downgraded Novo Nordisk’s rating to sell, breaking the trend of Wall Street analysts who had been reluctant to advise selling the stock. Analyst Emmanuel Papadakis cut his price target by 9% to 265 kroner. The Danish Ozempic maker’s shares have plunged 70% from their all-time high. This downgrade marks a significant turning point in market sentiment toward the Danish pharmaceutical group.
Source: Read the original article
